Drug Type Small molecule drug |
Synonyms Cannabidiol/delta-9-tetrahydrocannabivarin, Cannabidiol/tetrahydrocannabivarin-9, Tetrahydrocannabivarol-9/cannabidiol + [3] |
Target |
Mechanism CB1 antagonists(Cannabinoid CB1 receptor antagonists), CB2 antagonists(Cannabinoid CB2 receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC21H30O2 |
InChIKeyQHMBSVQNZZTUGM-ZWKOTPCHSA-N |
CAS Registry13956-29-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 2 | GB | - | |
Diabetes Mellitus, Type 2 | Phase 2 | - | - | |
Dyslipidemias | Phase 2 | GB | - | |
Dyslipidemias | Phase 2 | - | - | |
Metabolic Syndrome | Phase 2 | GB | - | |
Metabolic Syndrome | Phase 2 | - | - | |
Obesity | Phase 2 | GB | - |
Phase 1 | 22 | Inje cocktail (Inje Cocktail) | khshdvxqqt(uxsdhadqcc) = okgrrznybl slejmutlpq (boiwxlrpej, lzxkesovuy - nbihdcrvno) View more | - | 24 Jul 2023 | ||
Inje cocktail+THC Cannabis extract (Inje Cocktail + THC Extract) | khshdvxqqt(uxsdhadqcc) = ltbnyfxitc slejmutlpq (boiwxlrpej, avyusrljzd - mvzfmnzdmq) View more | ||||||
Phase 2 | 2 | (GWP42003 : GWP42004 (40:1)) | gxadnhieri(ydkxopkhvg) = gnnehqwzpt jkhgujocdg (awwlsaqniv, vujqgvshgr - rfrfopgdfr) View more | - | 01 Nov 2013 | ||
Placebo (Placebo) | gxadnhieri(ydkxopkhvg) = bmrxleqybm jkhgujocdg (awwlsaqniv, shxqxzrnyc - yykrkexvlp) View more |